Corcept Therapeutics, a California-based company, submitted new drug applications to the FDA and received analyst ratings.
2 reports, 2 independent
Updated Jul 27
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Corcept Therapeutics, a California-based company, submitted new drug applications to the FDA and received analyst ratings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
-
Food and Drug Administration
government organization in Nonthaburi, Thailand
Related events
- Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.
- Corcept Therapeutics is seeking final approval from the European Commission for a cancer therapy already approved in the US market.
- FDA approval boosted Revolution Medicines, Inc.'s stock price.
- Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.
Coverage
Newest first; wire copies grouped- Insider MonkeyCorcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 11 Best Long Term Low Risk Stocks to Invest in. The company co
- Business WireCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call REDWOOD CITY, Calif., July 24, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorpo